

RANDOX

# EARLY DIAGNOSIS CAN MAKE A DIFFERENCE

## Diabetic Kidney Disease Test

Biochip Array provides risk assessment and monitoring of diabetic patients in clinic to triage patients and identify progression of Diabetic Kidney Disease (DKD).



**£440m** Invested  
in Biochip



**153 million** tests  
performed globally



**203** patents



**643 Million**

people estimated  
to be living with  
diabetes by 2030

**£11.4 Billion**

DKD cost per million  
diabetics in the UK  
by 2025

**40%**

of diabetics develop  
end-stage renal failure

**21%**

of type 1 diabetes  
deaths are due to  
DKD

### Why Biochip?



Provide **treatment before**  
significant kidney **damage begins**



**Monitors the effectiveness**  
of treatments & lifestyle changes



**Rapid results within**  
**60 minutes**



**Better patient management** by  
identifying diabetic patients at risk


Used in research settings to date.

# Data-Driven Risk Stratification

A recent study demonstrated four biomarkers which could be used to clinically predict the progression of type 2 diabetes to DKD. Biochip is the only product on the market which allows for simultaneous measurement of the four markers within 60 minutes. This can allow earlier, more effective treatment and delay the need for dialysis or kidney transplant.

A patient triage pathway using Randox Biochip Technology allows patients at highest risk to be referred for urgent investigation while reducing the need for referrals for those at low risk.

## Patient Pathway



## Biomarkers

sTNFR1	sTNFR2	H-FABP	Midkine
--------	--------	--------	---------

## Product Information

 <b>Sample Type</b> Serum	 <b>Samples Per Cartridge</b> 2	 <b>Sample Volume</b> 250µl	 <b>Result Type</b> Quantitative	 <b>Time to Result</b> 60 Minutes
--	--	--	--	--

**Kidney Dysfunction Biochip** – For use on the Evidence MultiSTAT analyser

marketing@randox.com | randox.com